How to Help Your Patients Find Prolia in Stock: A Provider's Guide

When a patient calls to say their Prolia appointment was cancelled because the drug isn't in stock, your response matters enormously. Prolia (denosumab) has a unique pharmacology: stopping even briefly causes rapid rebound bone resorption and elevated fracture risk. This guide provides a clinical workflow to help your team proactively manage Prolia access — and troubleshoot quickly when problems arise.

Understanding the Prolia Supply Chain

Prolia does not go from manufacturer to retail pharmacy shelf. The supply chain looks like this: Amgen (manufacturer) → specialty distributor/specialty pharmacy → your practice or infusion center → patient. This means supply issues rarely originate with the manufacturer — they typically occur at the insurer authorization level, the specialty pharmacy ordering level, or the clinical scheduling level. Knowing this helps you troubleshoot efficiently.

Proactive Workflow: Preventing Delays Before They Happen

The best way to handle a Prolia delay is to prevent it. Implement these steps into your practice workflow:

1. Build a Prolia patient registry. Maintain a list of all patients due for Prolia injections with dates and insurance info. Review this monthly.
2. Verify insurance 4–6 weeks in advance. Check whether the plan now requires a biosimilar. Confirm the prior authorization is active. Initiate renewal if expiration is within 60 days.
3. Order the drug 2–3 weeks before the injection date. Don't wait until the appointment week to order from your distributor.
4. Identify which biosimilar your distributor stocks. If your preferred distributor doesn't carry brand Prolia, confirm which biosimilar (Jubbonti, Bomyntra, etc.) they have available and verify your insurer will cover it.

When Prolia Isn't Available at Your Practice: Referral Options

If your office can't source Prolia or an approved biosimilar in time, don't simply reschedule the patient for 6 weeks later. Instead, consider warm-referral to:

• Local infusion centers: Hospital-based or freestanding infusion centers often stock Prolia and denosumab biosimilars for cancer patients, and can frequently accommodate non-oncology biologics.
• Rheumatology practices: Rheumatologists routinely administer denosumab and often maintain reliable specialty drug supplies.
• Endocrinology practices: Endocrinologists who manage osteoporosis patients are also a reliable referral destination.

Provide your patient with a referral note confirming diagnosis, last injection date, and next scheduled dose. Timeliness matters — even a 2–4 week overage increases fracture risk.

Documenting for Prior Authorization Appeals

When prior authorization is denied, a letter of medical necessity from the prescriber can be decisive. Effective PA appeal letters for Prolia should include:

• Patient's T-score and fracture history
• Documentation of prior bisphosphonate use (duration, doses, reason for discontinuation)
• Clinical justification for denosumab over bisphosphonates (e.g., renal impairment, GI intolerance, compliance history)
• Specific risk of vertebral fracture rebound if injection is delayed

Leveraging Amgen SupportPlus for Access Support

Amgen SupportPlus (1-866-264-2778) offers dedicated support to both patients and providers. Their reimbursement specialists can assist with prior auth, formulary exception requests, and patient co-pay assistance. For commercially insured patients, the Amgen SupportPlus Co-Pay Program can reduce the cost to $0 per dose. For uninsured patients, the Patient Assistance Program can provide free Prolia for up to one year.

Using medfinder to Locate Nearby Dispensing Providers

When your team needs to quickly identify which local practices have Prolia or a denosumab biosimilar in stock, medfinder for providers is a valuable tool. We contact local dispensing sites to check availability, so your staff doesn't have to spend hours on hold. This can save your team significant time while ensuring your patient gets their injection on schedule.

Related: Prolia Shortage: What Providers and Prescribers Need to Know in 2026.